MedTrace Logo

Psychodynamic Psychotherapy for Psychosis

NCT04415541 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-10-25

No results posted yet for this study

Summary

The broad goals of our pilot study are to (1) determine whether psychodynamic psychotherapy for psychosis (PPfP), relative to treatment as usual (TaU), can maintain or augment clinical and functional benefits for patients who have achieved initial recovery in our coordinated specialty care (CSC) early psychosis treatment program; (2) to conduct novel empirical study of how various psychodynamic factors may inform candidate selection, mediate therapeutic effects, and influence relational aspects of the therapy; and (3) to conduct a detailed study of how features of therapist and patient speech and behavior influence therapeutic outcomes, therapeutic alliance alliance, and relational process. This registration focuses on the first goal.

Conditions

  • Psychotic Disorders

Interventions

BEHAVIORAL

Psychodynamic Psychotherapy

Intensive psychotherapy that is psychodynamically oriented.

BEHAVIORAL

Usual Care

Conventional treatment offered in the community.

Sponsors & Collaborators

  • Yale University

    lead OTHER

  • University of Southern California

    collaborator OTHER

  • American Psychoanalytic Association

    collaborator UNKNOWN

Principal Investigators

  • Keith Gallagher, MD · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2021-08-31
Completion
2021-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04415541 on ClinicalTrials.gov